DocMorris accelerates Rx growth to 78% in Q3; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again
DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris accelerates Rx growth to 78% in Q3; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again 15-Oct-2026 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════ Frauenfeld, 15 October 2026 Press release Ad hoc announcement pursuant to Art. 53 LR DocMorris accelerates Rx growth to 78% in Q3; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again • Revenue growth of 21.5% in Q3 and 15.5% in the first nine months • Strong acceleration of Rx growth to 78.3% versus Q3 2025; plus 33.5% versus Q2 2026 • Non-Rx up 5.5% in Q3, of which Digital Services up 46.1% • Adjusted EBITDA of CHF 0.6 million in Q3 • Revenue and adjusted EBITDA guidance for 2026 increased CEO Walter Hess says: “Our revenue growth accelerated again in the third quarter of 2026, demonstrating that our offering is well received by patients. We will continue to consistently leverage this Rx momentum to expand our custome
DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris accelerates Rx growth to 78% in Q3; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again 15-Oct-2026 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════ Frauenfeld, 15 October 2026 Press release Ad hoc announcement pursuant to Art.
6 million in Q3 • Revenue and adjusted EBITDA guidance for 2026 increased CEO Walter Hess says: “Our revenue growth accelerated again in the third quarter of 2026, demonstrating that our offering is well received by patients. 6 million. 4 million. 0 per cent.
0 per cent in Q2 compared to Q1 2026). 5 per cent. 5 per cent. 9 million, with a further increase in earnings contribution.
0 per cent. 1 million. 2 million were added in the third quarter of 2026, with the number of new Rx customers increasing at an above-average rate. 6 million in the third quarter, thus reaching the targeted breakeven ahead of schedule.
6 million. 0 per cent. 6 per cent in the first nine months, with a continued positive trend in the fourth quarter. 0 million.
3 per cent. 6 million convertible bond maturing in 2028. The repurchase was financed by issuing a new convertible bond maturing in 2031. This move extends the company's maturity profile while simultaneously reducing its relative financing costs.
5 million); • Capital expenditure remains unchanged at below CHF 30 million. Management confirms the target of achieving free cash flow breakeven during 2027, following the achievement of the adjusted EBITDA breakeven target during 2026 in the third quarter. Medium-term targets remain unchanged.
com, phone: +49 171 864 888 1 Agenda 12 November 2026 Capital Markets Day in Heerlen (NL) 19 January 2027 Revenue 2026 18 March 2027 2026 Full-year results and outlook 2027 (hybrid/Zurich, conference call/webcast) 15 April 2027 Q1/2027 Trading Update 12 May 2027 Annual General Meeting, Zurich DocMorris The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,500 doctors.
DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving over 12 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM).
com. Disclaimer This announcement contains certain forward-looking statements about DocMorris AG and its business, either explicitly or implicitly. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, financial position, performance or achievements of DocMorris AG to differ materially from the future results, performance or achievements expressed or implied by such forward-looking statements.
DocMorris AG is making this announcement available as of today's date and undertakes no obligation to update the forward-looking statements contained herein as a result of new information, future events or for any other reason. 5 ^ 1 External revenue consists of the revenue of DocMorris plus online revenue of apotal, less revenue related to supplies to apotal. 6 ^ 2 All percentages are in local currency. 7 ^ 3 Consisting of OTC business and Digital Services (TeleClinic, Retail Media, Marketplace).
8 ^ 4 Customers supplied by DocMorris, either directly or through its partners. ══════════════════════════════════════════════════════════════════════════ End of Inside Information ══════════════════════════════════════════════════════════════════════════ Language: English Company: DocMorris AG Walzmühlestrasse 49 8500 Frauenfeld Switzerland ISIN: CH0042615283 Listed: SIX Swiss Exchange EQS News ID: 2416062 End of Announcement EQS News Service 2416062 15-Oct-2026 CET/CEST References Visible links 1. html#_ftn1 2. html#_ftn2 3.
html#_ftn3 4. html#_ftn4 5. html#_ftnref1 6. html#_ftnref2 7.
html#_ftnref3 8. html#_ftnref4